EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Epidemiological Impact of Nirsevimab on Admissions for Bronchiolitis in a Pediatric Emergency Department: A Single-Center Cohort Study

Emanuele Castagno iD, Carola Aschieri, Irene Ferri, Sara El Khbazi, Lorenzo Milani iD, Rosanna Irene Comoretto iD, Irene Raffaldi iD, Irene Tardivo, Marco Spada iD, Claudia Bondone, Franca Fagioli iD

Viruses · 16.04.2026 · 18 (4) · 469

DOI: 10.3390/v18040469 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Viruses, online erschienen am 16.04.2026. Verfasst von Emanuele Castagno und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Emergency, Regina Margherita Children's Hospital, 10126 Turin, Italy. Hauptthemen laut MEDLINE: Bronchiolitis, Emergency Service, Hospital, Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis in children < 24 months and a major public health concern, causing high rates of Emergency Department (ED) visits, hospitalizations, and Pediatric Intensive Care Unit (PICU) admissions. Nirsevimab is a recombinant monoclonal antibody recommended for all infants and high-risk children < 24 months. A retrospective single-center cohort study was conducted to evaluate the impact of nirsevimab introduction on bronchiolitis epidemiology in an Italian tertiary pediatric ED, accounting for 40,000 admissions/year. All children < 24 months who presented to our ED with bronchiolitis during two consecutive RSV seasons (first season: 1 October 2023 to 30 April 2024; second season: 1 October 2024 to 30 April 2025) were included. Descriptive and multivariate analyses are reported. Overall, 484 patients were analyzed (336 in 2023–2024; 148 in 2024–2025), with immunization coverage reaching 87.5% by April 2025. Compared with the previous season, RSV positivity decreased significantly (32.4% vs. 47.9%; p = 0.003) and was lower in immunized children (16.2% vs. 51.5%; p < 0.001). Immunization was associated with a reduced risk of RSV-positive swab in the second season (OR = 0.159, 95% CI: 0.059–0.397). Among RSV-negative patients, other respiratory viruses increased (p < 0.001), while co-infections increased in RSV-positive cases (p = 0.021). Hospitalization rates remained stable, though absolute admissions were halved. In conclusion, nirsevimab immunization reduced RSV burden, supporting its inclusion in universal prevention programs and the need for multicenter prospective studies to assess long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BronchiolitisEmergency Service, HospitalRespiratory Syncytial Virus InfectionsAntibodies, Monoclonal, HumanizedHumansInfantRetrospective StudiesFemaleMaleItalyHospitalizationEmergency Room VisitsRespiratory Syncytial Virus, HumanCohort StudiesSeasons

Stichwörter der Autor:innen

Respiratory syncytial virusbronchiolitisemergency departmentinfantsnirsevimab

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pediatric Emergency, Regina Margherita Children's Hospital, 10126 Turin, Italy.
  • Department of Pediatrics and Public Health Sciences, Postgraduate School of Pediatrics, University of Turin, 10126 Turin, Italy.
  • Department of Pediatrics, Regina Margherita Children's Hospital, University of Turin, 10126 Turin, Italy.
  • Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.
  • Department of Pediatrics and Public Health Sciences, University of Turin, 10126 Turin, Italy.
  • Pediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, 10126 Turin, Italy.

ORCID-Profile: Emanuele Castagno, Lorenzo Milani, Rosanna Irene Comoretto, Irene Raffaldi, Marco Spada, Franca Fagioli

Zitieren

APA

Castagno, E., Aschieri, C., Ferri, I., El Khbazi, S., Milani, L., Comoretto, R. I., Raffaldi, I., Tardivo, I., Spada, M., Bondone, C., & Fagioli, F. (2026). Epidemiological Impact of Nirsevimab on Admissions for Bronchiolitis in a Pediatric Emergency Department: A Single-Center Cohort Study. Viruses, 18(4), 469. https://doi.org/10.3390/v18040469

Vancouver

Castagno E, Aschieri C, Ferri I, El Khbazi S, Milani L, Comoretto RI, et al. Epidemiological Impact of Nirsevimab on Admissions for Bronchiolitis in a Pediatric Emergency Department: A Single-Center Cohort Study. Viruses. 2026;18(4):469. doi:10.3390/v18040469

BibTeX
@article{Castagno2026,
  author = {Castagno, Emanuele and Aschieri, Carola and Ferri, Irene and El Khbazi, Sara and Milani, Lorenzo and Comoretto, Rosanna Irene and Raffaldi, Irene and Tardivo, Irene and Spada, Marco and Bondone, Claudia and Fagioli, Franca},
  title = {Epidemiological Impact of Nirsevimab on Admissions for Bronchiolitis in a Pediatric Emergency Department: A Single-Center Cohort Study},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {4},
  pages = {469},
  doi = {10.3390/v18040469}
}
Kostenlos starten →